Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPatial Heterogeneity of INtratumoral drug distribution (SPHINX)
2025-520530-32-00Phase 4Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ribociclib, letrozole and anastrozole in breast cancer (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Concentration of aromatase inhibitor and ribociclib in different tumor regions. Planned start Jul 2025; status: authorised.
02
Drugs
ribociclibletrozoleanastrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-520530-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520530-32-00.